CJC-1295 (without DAC) vs Teriparatide
Well Studied vs Extensively Studied
synergistic Mechanism-based · 47% CJC-1295 (without DAC) and Teriparatide work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
CJC-1295 (without DAC) Teriparatide
Weight 3,367.97 Da 4,118 Da
Half-life 30 minutes - 2 hours ~1 hour (subcutaneous); ~5 minutes (intravenous)
Chain 30 amino acids 34 amino acids
Type GHRH analog Recombinant PTH fragment
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Teriparatide
01 FDA-approved for osteoporosis treatment
02 Actively builds new bone (anabolic)
03 Increases spine bone density by 5-9%
04 Reduces vertebral fracture risk by 65%
05 Reduces nonvertebral fractures by 35%
06 Works differently than antiresorptive drugs
07 Benefits seen within 3 months
08 Creates 'anabolic window' for bone growth
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Teriparatide
20mcg daily (FDA-approved dose) / Once daily at same time each day
Osteoporosis treatment 20 mcg Once daily
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Teriparatide
Injection site reactions
Nausea
Headache
Leg cramps
Dizziness
Joint pain
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Paget's disease of bone
Prior skeletal radiation therapy
History of skeletal malignancies
Metabolic bone diseases other than osteoporosis
Pre-existing hypercalcemia
Pregnancy
Research Evidence
CJC-1295 (without DAC) Teriparatide
Status Well Studied Extensively Studied
References 5 studies 4 studies
Latest November 2024 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.